Pacira Pharmaceuticals, Inc. (PCRX) Stock
Key stats
- Market cap
- $1.46B
- Price / Earnings ratio
- 38.8x
- EPS (TTM)
- $0.95
- Volume
- Loading
- 52-week high
- $36.67
- 52-week low
- $18.80
Source: third-party data provider, as of November 13, 2026
Compare with PCRX
Recent news
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
PCRX
Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
PCRX
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
PCRX
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
PCRXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 82.71
- MACD 12/26/9
- 1.50
- EMA 9 of MACD
- 1.89
- MACD histogram
- -0.40
- SMA 50
- $30.79
- Price above SMA 50
- EMA 50
- $32.23
- Price above EMA 50
- SMA 200
- $25.49
- Price above SMA 200
- EMA 200
- $26.82
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.61 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
PCRXPacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
PCRXPacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
PCRXStocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
PCRX
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
PCRX
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
PCRX
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
PCRX
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly
PCRX
Why Pacira BioSciences Skyrocketed Today
Why Pacira BioSciences Skyrocketed Today
PCRX
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
PCRXNews tone: automated (AI) classification of the article's content, not a price prediction.
About Pacira Pharmaceuticals, Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Frank D. Lee | CEO & Director | 1968 |
| Mr. Shawn M. Cross | Chief Financial Officer | 1968 |
| Ms. Kristen Williams Esq., J.D. | Chief Administrative Officer & Secretary | 1974 |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer | 1975 |
| Mr. Brendan P. Teehan | Chief Commercial Officer | 1969 |
| Ms. Lauren Bullaro Riker | Principal Accounting Officer & Senior VP of Finance | 1979 |
| Ms. Susan Mesco | Head of Investor Relations | — |
| Mr. Anthony Molloy III, Esq. | Chief Legal & Compliance Officer | 1974 |
| Mr. Christopher C. Young | Chief Manufacturing Officer | 1972 |
| Ms. Krys Corbett Esq. | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 82.71
- MACD 12/26/9
- 1.50
- EMA 9 of MACD
- 1.89
- MACD histogram
- -0.40
- SMA 50
- $30.79
- Price above SMA 50
- EMA 50
- $32.23
- Price above EMA 50
- SMA 200
- $25.49
- Price above SMA 200
- EMA 200
- $26.82
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $28.00
- Average
- $34.08
- High
- $36.50
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.0 | +12.9 | ||||||||||
| 2022 | +2.6 | +6.9 | +12.8 | -4.3 | -14.9 | -8.1 | -2.2 | -6.6 | +1.8 | -6.0 | -8.0 | -18.3 |
| 2023 | +1.1 | +4.9 | -5.9 | +9.5 | -18.4 | +5.3 | -9.3 | -1.9 | -13.7 | -5.4 | -3.6 | +21.3 |
| 2024 | +1.8 | -6.5 | +1.2 | -9.9 | +12.5 | -7.4 | -27.4 | -25.0 | -0.9 | +8.5 | +2.1 | +5.8 |
| 2025 | +43.6 | -6.6 | +8.2 | +11.8 | -3.4 | -8.9 | -9.3 | +20.8 | -5.3 | -15.4 | +6.2 | +9.2 |
| 2026 | -16.0 | +3.3 | +6.2 | +11.8 | -5.0 | +10.5 | +5.5 | -3.8 | -5.4 | +45.5 | +0.2 |
